Antidepressant dose reduction and the risk of relapse in major depressive disorder

Psychotherapy and Psychosomatics

Volumn 76, Issue 5, 2007, Pages 266-270

  Papakostas, George I ^a   Perlis, Roy H ^a   Seifert, Cheryl ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressant dose reduction; Antidepressants, dosing and relapse; Depression; Depressive relapse; Dose of depressants; Major depressive disorder; Relapse recurrence rates

Indexed keywords

AMINEPTINE; ANTIDEPRESSANT AGENT; IMIPRAMINE; MAPROTILINE; PAROXETINE; PHENELZINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DOSE REDUCTION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; RELAPSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; RECURRENCE; RISK FACTORS;

EID: 34547862780     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000104702     Document Type: Article

References (23)

1. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661.
2. Papakostas GI, Schwartz TL: Pharmacotherapeutic strategies to enhance tolerability and adherence in MDD; in Petersen TJ, Schwartz TL (eds): Depression: Treatment Strategies and Management. New York, Taylor & Francis, 2006, vol 1, pp 201-215.
3. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
4. Laird NM, Mosteller F: Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
5. Mosteller F, Colditz GA: Understanding research synthesis (meta-analysis). Annu Rev Public Health 1996;17: 1-23.
6. Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-1129.
7. Davidson J, Raft D: Use of phenelzine in continuation therapy. Neuropsychobiology 1984;11:191-194.
8. Rouillon F, Serrurier D, Miller HD, Gerard MJ: Prophylactic efficacy of maprotiline on unipolar depression relapse. J Clin Psychiatry 1991;52:423-431.
9. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993;27:139-145.
10. Ferreri M, Colonna L, Leger JM: Efficacy of amineptine in the prevention of relapse in unipolar depression. Int Clin Psychopharmacol 1997;12:S39-S45.
11. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R: Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry 1998;59:229-232.
12. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
13. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Publ No (ADM) 76-338. Rockville, National Institute of Mental Health, 1976.
14. Montgomery SA, Asberg A: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
15. Baldessarini RJ, Ghaemi SN, Viguera AC: Tolerance in antidepressant treatment. Psychother Psychosom 2002;71:177-179.
16. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part 1: Dose increase. Psychother Psychosom 2002;71:190-194.
17. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part 2: Reinitiation of antidepressant treatment. Psychother Psychosom 2002;71:195-199.
18. Montgomery SA, Dunbar G: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993;8:189-195.
19. Wise TN: Curiosity and crisis. Psychother Psychosom 2006;75:199-201.
20. Fava GA: The intellectual crisis of psychiatric research. Psychother Psychosom 2006;75:202-208.
21. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ: The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res 2000;34:3-10.
22. Khan A, Khan SR, Shankles EB, Polissar NL: Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials. Int Clin Psychopharmacol 2002;17:281-285.
23. Khan A, Brodhead AE, Kolts RL: Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 2004;19:157-160.